Study on Adding Venetoclax to Usual Chemotherapy for High-Grade B-Cell Lymphomas

Program Overview

The purpose of this study is to see if adding venetoclax to the usual chemotherapy drugs can improve treatment outcomes for patients with high-grade B-cell lymphomas. Venetoclax may help stop cancer cells from growing by blocking a protein called Bcl-2. The standard chemotherapy includes drugs like rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide, which work in different ways to kill cancer cells or stop them from spreading. The study aims to find out if this combination can increase the chances of the cancer going into remission and not coming back.

Description

The main goal of this study is to compare how long patients live without their cancer getting worse when treated with rituximab-based chemotherapy plus venetoclax versus rituximab-based chemotherapy alone. The study will also look at overall survival, event-free survival, and response rates between the two treatment groups. Researchers will assess the safety and side effects of the treatments and explore how different factors, like protein expression in the cancer cells, might affect outcomes.

Participants will be randomly assigned to one of two groups. In one group, patients will receive the standard chemotherapy regimen, while in the other group, patients will receive the same chemotherapy plus venetoclax. The treatment will be given in cycles, with each cycle lasting 21 days, and will continue for up to six cycles unless the cancer progresses or side effects become too severe.

Throughout the study, patients will undergo various tests, including PET and CT scans, blood tests, and possibly bone marrow biopsies and lumbar punctures, to monitor their response to treatment. After completing the treatment, patients will have regular follow-up visits to check their health and cancer status for up to 10 years.

Eligibility Criteria

Locations